Pipeline—creating tomorrow's vaccines today

The world urgently needs new tools to help solve some of our greatest infectious disease challenges. Novavax is applying our unique technology to address current and emerging threats.

Novavax continually conducts clinical trials and investigations and gathers real-world evidence to develop vaccines aimed at addressing public health threats. Our scientists in our research and development (R&D) programs are committed to the efficient delivery of new vaccines while maintaining the safety of patients who take part in our trials.

Our pipeline

Novavax aims to develop innovative vaccines that may help improve lives and fight infectious diseases around the world. The table below lists our selected research and development priorities.

Our Matrix-M adjuvant technology

Investigational vaccines listed below with the Matrix-M symbol have been developed with the Matrix-M adjuvant.

Learn more about our technology platform

Learn more about our disease areas of focus

Vaccines in Novavax Pipeline and Status
Therapeutic area	Candidate	Technology	Phase of trial				Authorized use
			Preclinical	Phase 1	Phase 2	Phase 3
Respiratory diseases COVID-19	Novavax COVID-19 Omicron vaccine Pipeline details	Matrix-M™ adjuvant				Phase 3 in progress
Respiratory diseases COVID-19	Novavax COVID-19 vaccine (NVX-CoV2373) Pipeline details	Matrix-M™ adjuvant					Authorized^*
Respiratory diseases Seasonal influenza	Influenza (qNIV) vaccine Pipeline details	Matrix-M™ adjuvant				Phase 3 in progress
Respiratory diseases COVID-19 + seasonal influenza	COVID-influenza combination (CIC) vaccine Pipeline details	Matrix-M™ adjuvant			Phase 1/2
Parasitic diseases Malaria	R21^‡ Pipeline details	Matrix-M™ adjuvant			Phase 2b in progress